X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (25) 25
index medicus (25) 25
oncology (16) 16
female (12) 12
male (10) 10
cancer (9) 9
colorectal cancer (9) 9
aged (8) 8
animals (8) 8
middle aged (8) 8
care and treatment (7) 7
chemotherapy (7) 7
adult (6) 6
cell line, tumor (6) 6
cetuximab (6) 6
gene expression (6) 6
kras (6) 6
prognosis (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
research (6) 6
antineoplastic agents - therapeutic use (5) 5
colorectal neoplasms - drug therapy (5) 5
colorectal neoplasms - pathology (5) 5
medicine & public health (5) 5
metastasis (5) 5
mice (5) 5
protein kinase inhibitors - pharmacology (5) 5
therapy (5) 5
aged, 80 and over (4) 4
braf (4) 4
cell biology (4) 4
colon cancer (4) 4
colonic neoplasms - drug therapy (4) 4
colonic neoplasms - genetics (4) 4
colonic neoplasms - pathology (4) 4
expression (4) 4
hct116 cells (4) 4
metaanalysis (4) 4
metastatic colorectal-cancer (4) 4
receptor, epidermal growth factor - metabolism (4) 4
surgery (4) 4
survival rate (4) 4
tumors (4) 4
1st-line treatment (3) 3
activation (3) 3
apoptosis (3) 3
biology (3) 3
biotechnology & applied microbiology (3) 3
cancer research (3) 3
cancer therapies (3) 3
carcinoma (3) 3
cetuximab plus irinotecan (3) 3
chemoradiotherapy (3) 3
colorectal neoplasms - genetics (3) 3
colorectal-cancer (3) 3
development and progression (3) 3
digestive system diseases (3) 3
egfr (3) 3
follow-up studies (3) 3
genetic aspects (3) 3
genetics (3) 3
growth-factor receptor (3) 3
ht29 cells (3) 3
immunohistochemistry (3) 3
map kinase signaling system (3) 3
medicine (3) 3
metastatic colorectal cancer (3) 3
molecular subgroups (3) 3
monoclonal antibodies (3) 3
neoplasm metastasis (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
oxaliplatin (3) 3
panitumumab (3) 3
phase-ii (3) 3
phosphorylation (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
quinazolines - pharmacology (3) 3
research article (3) 3
resistance (3) 3
signal transduction - drug effects (3) 3
squamous-cell carcinoma (3) 3
survival (3) 3
xenograft model antitumor assays (3) 3
abridged index medicus (2) 2
acquired-resistance (2) 2
adenocarcinoma (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - pathology (2) 2
adenocarcinoma - radiotherapy (2) 2
adenocarcinoma - surgery (2) 2
adolescent (2) 2
amphiregulin (2) 2
analysis (2) 2
anti-egfr moabs (2) 2
anti-egfr resistance (2) 2
anti-egfr sensitivity (2) 2
anti-egfr treatments (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis - drug effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cell Reports, ISSN 2211-1247, 09/2015, Volume 12, Issue 12, pp. 1978 - 1985
Most ( ) mutant melanomas are sensitive to selective BRAF inhibitors, but mutant colon cancers are intrinsically resistant to these drugs because of feedback... 
COLON-CANCER | SHP2 PTPN11 | LUNG-CANCER | MEK INHIBITION | BRAF(V600E) INHIBITION | GROWTH | PROTEIN-TYROSINE PHOSPHATASES | RAF INHIBITORS | MUTATIONS | NOONAN-SYNDROME | CELL BIOLOGY | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism | RNA, Small Interfering - genetics | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Colonic Neoplasms - genetics | Colonic Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Genomic Library | ras Proteins - metabolism | Colonic Neoplasms - metabolism | MAP Kinase Signaling System | Receptor, Epidermal Growth Factor - metabolism | Melanoma - genetics | Indoles - pharmacology | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Transduction, Genetic | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Melanoma - pathology | Sulfonamides - pharmacology | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | High-Throughput Nucleotide Sequencing | Mice | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics | Genetic Vectors | Drug Resistance, Neoplasm - drug effects | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2013, Volume 133, Issue 9, pp. 2089 - 2101
The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of... 
lung cancer | colorectal cancer | combination of molecular targeted therapies | MEK inhibitors | SIGNALING PATHWAYS | ACTIVATION | RAS | AZD6244 | ARRY-142886 | IDENTIFICATION | PI3K | ONCOLOGY | SELUMETINIB | KRAS | TUMOR-GROWTH | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Gene Expression Profiling | TOR Serine-Threonine Kinases - antagonists & inhibitors | Colorectal Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Colorectal Neoplasms - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | PTEN Phosphohydrolase - metabolism | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cell Cycle - drug effects | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Colorectal cancer | Tumors | Chemotherapy | Pharmacology | Kinases | Lung cancer | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 2841 - 2841
Journal Article
Gut, ISSN 0017-5749, 07/2014, Volume 64, Issue 6, pp. 921 - 928
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 1218 - 1218
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 09/2017, Volume 9, Issue 9, pp. 2819 - 2823
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2013, Volume 19, Issue 10, pp. 2688 - 2698
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 2013, Volume 6, pp. 53 - 58
Purpose: The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as... 
Chemorefractory | Colorectal cancer | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | colorectal cancer | OXALIPLATIN | FLUOROURACIL | TRIAL | chemorefractory | CETUXIMAB | THERAPY | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | RANDOMIZED PHASE-III | IN-VIVO | bevacizumab | IRINOTECAN | Chemotherapy | Drug therapy | Methods | Cancer | Metastasis | Growth factors | Disease control
Journal Article
Cell, ISSN 0092-8674, 04/2016, Volume 165, Issue 2, pp. 317 - 330
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2010, Volume 16, Issue 20, pp. 4990 - 5001
Purpose: Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the... 
APOPTOSIS | ACTIVATION | THERAPY | ANGIOGENESIS | ONCOLOGY | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | TUMOR-GROWTH | EXPRESSION | CARCINOMA | EGFR | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - pathology | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antibodies, Monoclonal, Humanized | Benzenesulfonates - pharmacology | Colorectal Neoplasms - drug therapy | Female | Quinazolines - administration & dosage | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Colorectal Neoplasms - enzymology | Receptor, Epidermal Growth Factor - biosynthesis | Lung Neoplasms - enzymology | Pyridines - administration & dosage | Cell Growth Processes - drug effects | Antibodies, Monoclonal - pharmacology | HCT116 Cells | Receptors, Vascular Endothelial Growth Factor - biosynthesis | Drug Synergism | HT29 Cells | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Animals | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2011, Volume 11, Issue 1, pp. 126 - 126
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 4162 - 4162
Journal Article
Journal of Interventional Cardiac Electrophysiology, ISSN 1383-875X, 11/2013, Volume 38, Issue 2, pp. 101 - 106
Journal Article